How has been the historical performance of Eiko Lifescience?

Answer:The historical performance of Eiko Lifescience shows significant growth from Mar'18 to Mar'25.

Breakdown:
Eiko Lifescience's net sales increased dramatically from 2.34 Cr in Mar'18 to 37.66 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 2.34 Cr in Mar'18 to 37.66 Cr in Mar'25. The company's total expenditure also grew, reaching 34.90 Cr in Mar'25, up from 1.99 Cr in Mar'18. Operating profit, which was 0.35 Cr in Mar'18, turned positive at 3.48 Cr in Mar'25, indicating improved operational efficiency. Profit before tax transitioned from 0.25 Cr in Mar'18 to 2.92 Cr in Mar'25, while profit after tax rose from 0.20 Cr to 2.18 Cr in the same period. The earnings per share (EPS) improved significantly from 0.51 in Mar'18 to 1.53 in Mar'25. On the balance sheet, total assets grew from 10.95 Cr in Mar'18 to 66.10 Cr in Mar'25, with total liabilities increasing from 10.95 Cr to 66.10 Cr as well. The cash flow from operating activities showed a positive trend, reaching 2.00 Cr in Mar'25, while the closing cash and cash equivalents increased to 11.00 Cr from 0.00 Cr in Mar'20. Overall, Eiko Lifescience has demonstrated substantial growth in revenue, profitability, and asset base over the years.